Company: PCRX
Filing Date: 2025-04-17
Form Type: DEFA14A
Source: 0001104659-25-036098
Chunk: 1

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-17
Form: DEFA14A
Chunk 1
---
0:

| · | Treating more than 3 million patients per year; |

| · | Achieving a double-digit compounded annual growth rate for revenue; |

| · | Improving gross margins by 5 percentage points over 2024; |

| · | Expanding the company’s clinical pipeline with 5 novel programs in development; and |

| · | Establishing 5 new partnerships including pipeline and commercial agreements. |

In addition to the 5x30 plan, today the company announced the
following initiatives focused on enhancing value creation.

| · | Repurchase Authorization.                                                                          
 The Board of Directors has authorized a share repurchase program of up to an aggregate of          
 $300 million with respect to the company’s common stock, under the same terms as the               
 authorization announced on May 7, 2024 and replacing the prior authorization. The                  
 Pacira Board and management team remain committed to a diligent, strategic approach to repurchases 
 that aligns with the company’s long-term objectives and enhances shareholder value.                
 The share repurchase authorization expires at the end of December 2026.                            |

| · | Commitment to Efficiency and Margin Expansion. The Pacira Board and management team are committed to enhancing the company’s               
 operational efficiency and expect to prioritize opportunities to drive margin expansion at the pre-tax net income level to further enhance 
 value for shareholders.                                                                                                                    |

Frank D. Lee, chief executive officer of Pacira BioSciences,
said, “This increased share repurchase authorization underscores the Board’s confidence in Pacira’s growth strategy
and our commitment to delivering value to shareholders. Our recently established EXPAREL exclusivity runway extends to 2039 and provides
long-term visibility that empowers us to confidently execute our 5x30 strategy as we generate significant cash flow. We have already made
significant progress implementing our value creation plan and remain focused on executing with discipline, positioning the company for
growth and accelerating our transition into an innovative biopharmaceutical organization and therapeutic area leader in musculoskeletal
pain and adjacencies. We look forward to building on our momentum and executing on our 5x30 strategy to accelerate long-term growth and
drive innovation to transform how pain is managed.”

About Pacira

Pacira delivers innovative, non-opioid pain therapies to
transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome
injectable suspension), a long-acting local analgesic